Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ViroLogic (VLGC) -- Ignore unavailable to you. Want to Upgrade?

To: creddell who wrote (51)	10/31/2001 7:22:40 PM
From: creddell	Respond to of 59

on further reflection would a brokerage house be accumulating? chuck

To: creddell who wrote (51)	11/1/2001 6:19:35 AM
From: blackmerlin	Read Replies (1) \| Respond to of 59

An agreement with Triangle Pharmaceuticals & VLGC was featured on p.5 of Genetic Engineering News right across from the prominent contents page of Oct. 15, 2001. I got a copy this week in the mail. That "Collaborations & Agreements" update is part of the current issue of GEN now. The news article read that Triangle will use ViroLogic's phenotypic drug-resistant assay, PhenoSense HIV, to assess drug activity of new antiretroviral agents against HIV. Regards, Jake Blackmerlin